{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+HCl&page=4", "query": { "intervention": "Diphenhydramine HCl", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 258, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+HCl&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+HCl&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T05:22:08.490Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04846348", "title": "Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Mastocytoses" ], "interventions": [ { "name": "Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Joseph Butterfield", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1, "start_date": "2021-07-26", "completion_date": "2021-09-10", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04846348" }, { "nct_id": "NCT04580121", "title": "A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "RO7283420", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Paracetamol/acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2020-11-04", "completion_date": "2023-08-09", "has_results": false, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 2, "location_summary": "Sacramento, California • Houston, Texas", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04580121" }, { "nct_id": "NCT01495858", "title": "Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain, Postoperative" ], "interventions": [ { "name": "Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)", "type": "DRUG" }, { "name": "Naproxen Sodium 440 mg (BAYH6689)", "type": "DRUG" }, { "name": "DPH 50 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 267, "start_date": "2011-12", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 2, "location_summary": "Austin, Texas • Salt Lake City, Utah", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495858" }, { "nct_id": "NCT02495077", "title": "Effects of Inhibiting Early Inflammation in Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant" ], "interventions": [ { "name": "Infliximab", "type": "BIOLOGICAL" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Thymoglobulin®", "type": "BIOLOGICAL" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Loratadine", "type": "DRUG" }, { "name": "Placebo for Infliximab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2015-11-02", "completion_date": "2021-07-23", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02495077" }, { "nct_id": "NCT01248962", "title": "Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 146, "start_date": "2010-11", "completion_date": "2018-08", "has_results": true, "last_update_posted_date": "2019-10-02", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01248962" }, { "nct_id": "NCT05219604", "title": "Central Nervous System Effects Following Infusion of Diphenhydramine Using Pharmacokinetic and Pharmacodynamic Modeling", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Central Nervous System Effects of Diphenhydramine", "Pharmacokinetics of Diphenhydramine" ], "interventions": [ { "name": "DiphenhydrAMINE Injectable Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dent Neuroscience Research Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 3, "start_date": "2022-03-15", "completion_date": "2022-10-04", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 1, "location_summary": "Amherst, New York", "locations": [ { "city": "Amherst", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05219604" }, { "nct_id": "NCT00078559", "title": "Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplantation", "Kidney Disease" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Kidney transplant", "type": "PROCEDURE" }, { "name": "Methylprednisolone (or equivalent)", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Trimethoprim (TMP)/Sulfa (Bactrim, Septra)", "type": "DRUG" }, { "name": "Valgancyclovir", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" }, { "name": "Pentamidine", "type": "DRUG" }, { "name": "Clotrimazole", "type": "DRUG" }, { "name": "Nystatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2003-11", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078559" }, { "nct_id": "NCT01455389", "title": "TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "DOTAP:Chol-TUSC2", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genprex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-02", "completion_date": "2020-09-28", "has_results": false, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01455389" }, { "nct_id": "NCT00223691", "title": "Treatment of Orthostatic Hypotension in Autonomic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autonomic Failure", "Orthostatic Hypotension" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Acarbose", "type": "DRUG" }, { "name": "Pyridostigmine Bromide", "type": "DRUG" }, { "name": "Yohimbine", "type": "DRUG" }, { "name": "Midodrine HCl", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Modafinil", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "water intake", "type": "OTHER" }, { "name": "Diphenhydramine Hydrochloride", "type": "DRUG" }, { "name": "Ranitidine HCL", "type": "DRUG" }, { "name": "Tranylcypromine", "type": "DRUG" }, { "name": "Ergotamine/ Caffeine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Pseudoephedrine", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Oxymetazoline 0.05% nasal solution", "type": "DRUG" }, { "name": "Bovril", "type": "DIETARY_SUPPLEMENT" }, { "name": "Acetazolamide", "type": "DRUG" }, { "name": "Rivastigmine tartrate", "type": "DRUG" }, { "name": "Carbidopa/levodopa", "type": "DRUG" }, { "name": "Inflatable abdominal binder", "type": "DEVICE" }, { "name": "inflatable abdominal binder (sham)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 389, "start_date": "2002-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00223691" }, { "nct_id": "NCT02735707", "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Community-acquired Pneumonia, Influenza, COVID-19" ], "interventions": [ { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Moxifloxacin or Levofloxacin", "type": "DRUG" }, { "name": "Piperacillin-tazobactam", "type": "DRUG" }, { "name": "Ceftaroline", "type": "DRUG" }, { "name": "Amoxicillin-clavulanate", "type": "DRUG" }, { "name": "Standard course macrolide", "type": "DRUG" }, { "name": "Extended course macrolide", "type": "DRUG" }, { "name": "No systemic corticosteroid", "type": "OTHER" }, { "name": "Fixed-duration Hydrocortisone", "type": "DRUG" }, { "name": "Shock-dependent hydrocortisone", "type": "DRUG" }, { "name": "Fixed-duration higher dose Hydrocortisone", "type": "DRUG" }, { "name": "No antiviral agent for influenza", "type": "OTHER" }, { "name": "Five-days oseltamivir", "type": "DRUG" }, { "name": "Ten-days oseltamivir", "type": "DRUG" }, { "name": "No antiviral agent for COVID-19", "type": "OTHER" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Hydroxychloroquine + lopinavir/ritonavir", "type": "DRUG" }, { "name": "Ivermectin", "type": "DRUG" }, { "name": "No immune modulation for COVID-19", "type": "OTHER" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Local standard venous thromboprophylaxis", "type": "DRUG" }, { "name": "Therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "Conventional low dose thromboprophylaxis", "type": "DRUG" }, { "name": "Intermediate dose thromboprophylaxis", "type": "DRUG" }, { "name": "Continuation of therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "No immunoglobulin", "type": "OTHER" }, { "name": "Convalescent plasma", "type": "BIOLOGICAL" }, { "name": "Delayed administration of convalescent plasma", "type": "BIOLOGICAL" }, { "name": "No vitamin C", "type": "OTHER" }, { "name": "Vitamin C", "type": "DRUG" }, { "name": "No antiplatelet", "type": "OTHER" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "P2Y12 inhibitor", "type": "DRUG" }, { "name": "No simvastatin", "type": "OTHER" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Eritoran", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Clinician-preferred mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "Protocolised mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "No renin-angiotensin system inhibitor", "type": "OTHER" }, { "name": "Angiotensin converting enzyme inhibitor", "type": "DRUG" }, { "name": "Angiotensin Receptor Blockers", "type": "DRUG" }, { "name": "ARB + DMX-200", "type": "DRUG" }, { "name": "No cysteamine", "type": "OTHER" }, { "name": "Cysteamine", "type": "DRUG" }, { "name": "Fixed-duration dexamethasone", "type": "DRUG" }, { "name": "Baloxavir Marboxil", "type": "DRUG" }, { "name": "Five-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "Ten-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "No endothelial modulator", "type": "OTHER" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "No Immune Modulator for Influenza", "type": "OTHER" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir + remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "UMC Utrecht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20000, "start_date": "2016-04-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-10-05T05:22:08.490Z", "location_count": 11, "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735707" } ] }